Xeomin is a botulinum toxin type A, so it works very similarly to Botox (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), Jeuveau (prabotulinumtoxinA-xvfs), and Daxxify (daxibotulinumtoxinA-lanm): by blocking signals between nerves and muscles so the injected muscle can’t contract and wrinkle the skin.Â
In terms of cost and longevity, it's quite similar to Botox and its competitors. One exception to this rule is Daxxify, the latest neuromodulator to earn FDA-approval, which is proven to last for six to nine months.Â
Xeomin also differs in that it doesn’t contain so-called complexing proteins (which are produced by the same bacteria that makes the toxin). The way Xeomin is manufactured removes these proteins from the active ingredient, botulinum toxin type A, which Harrison, New York-based oculoplastic surgeon Dr. James Gordon considers a plus. For certain patients, “it’s reassuring when a product has fewer unnecessary ingredients,” he says.Â
Xeomin does, however, contain the stabilizing protein human serum albumin, which makes it less pure than Daxxify, the only neuromodulator to be formulated without this blood-derived additive. Daxxify is also free of complexing proteins.Â
Some doctors theorize that these purer toxin formulations may be less likely to cause drug resistance over time, though this has yet to be clinically proven.
Whether a cleaner chemical composition gives a neuromodulator an edge over the competition is a point of debate among injectors. Houston-based dermatologic surgeon Dr. Melissa Chiang says that “all the protein detaches from Botox within one minute of injection, so there’s really no reason the effect of Xeomin should differ from Botox.”
Still, other doctors have reportedly found Xeomin to work for patients who’ve become unresponsive to other toxins.
Related: What’s the Difference Between Botox, Dysport, Xeomin, and Jeuveau?